Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 2, 2004, Pages 423-429

  Jacobson, Jeffrey M ^a,e   Israel, Robert J ^b   Lowy, Israel ^a,f   Ostrow, Nancy A ^a,e   Vassilatos, Linda S ^b   Barish, Melanie ^b   Tran, Diep N H ^b   Sullivan, Brian M ^b,d   Ketas, Thomas J ^b,d   O'Neill, Tobias J ^b   Nagashima, Kirsten A ^b   Huang, Wei ^c   Petropoulos, Christos J ^c   Moore, John P ^d   Maddon, Paul J ^b   Olson, William C ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e BETH ISRAEL MEDICAL CENTER   (United States)

^f MEDAREX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN; CD4 IMMUNOGLOBULIN G2; GLYCOPROTEIN GP 120; HYBRID PROTEIN; IMMUNOGLOBULIN G2; UNCLASSIFIED DRUG; VIRAL ENTRY INHIBITOR; VIRUS RNA;

ADULT; ADVANCED DISEASE; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOSYNTHESIS; CHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; T LYMPHOCYTE SUBPOPULATION; VIRION; VIRUS ADSORPTION; VIRUS LOAD; VIRUS NEUTRALIZATION;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CD4 IMMUNOADHESINS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD; VIRION;

EID: 9144250171     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.2.423-429.2004     Document Type: Article

References (38)

1. Allaway, G. P., K. L. Davis-Bruno, G. A. Beaudry, E. B. Garcia, E. L. Wong, A. M. Ryder, K. W. Hasel, M.-C. Gauduin, R. A. Koup, J. S. McDougal, and P. J. Maddon. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 11:533-539.
2. Berry, D. A., and B. W. Lindgren. 1996. Statistics: theory and methods. Wadsworth Publishing Company, Belmont, Calif.
3. Binley, J. M., B. Clas, A. Gettie, M. Vesanen, D. C. Montefiori, L. Sawyer, J. Booth, M. Lewis, P. A. Marx, S. Bonhoeffer, and J. P. Moore. 2000. Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. Virology 270:237-249.
4. Biscone, M. J., T. C. Pierson, and R. W. Doms. 2002. Opportunities and challenges in targeting HIV entry. Curr. Opin. Pharmacol. 2:529-533.
5. + cell model of chronic infection. J. Virol. 65:4645-4653.
6. Connor, R., K. E. Sheridan, D. Ceradini, S. Choe, and N. R. Landau. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-628.
7. Doms, R. W., and J. P. Moore. 2000. HIV-1 membrane fusion: targets of opportunity. J. Biol. 151:F9-14.
8. Donzella, G. A., D. Schols, S. W. Lin, J. A. Este, K. A. Nagashima, P. J. Maddon, G. P. Allaway, T. P. Sakmar, G. Henson, E. De Clercq, and J. P. Moore. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:72-77.
9. Equils, O., E. Garratty, L. S. Wei, S. Plaeger, M. Tapia, J. DeVille, P. Krogstad, M. S. Sim, K. Nielsen, and Y. J. Bryson. 2000. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy. J. Infect. Dis. 182:751-757.
10. Fauci, A. S., G. Pantaleo, S. Stanley, and D. Weissman. 1996. Immunopathogenic mechanisms of HIV infection. Ann. Intern. Med. 124:654-663.
11. Folks, T. M., K. A. Clouse, J. Justement, A. Rabson, E. Duh, J. H. Kehrl, and A. S. Fauci. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. 86:2365-2368.
12. Folks, T. M., J. Justement, A. Kinter, C. A. Dinarello, and A. S. Fauci. 1987. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238:800-802.
13. Folks, T. M., D. Powell, M. Lightfoote, S. Koenig, A. S. Fauci, S. Benn, A. Rabson, D. Daugherty, H. E. Gendelman, and M. D. Hoggan. 1986. Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus. J. Exp. Med. 164:280-290.
14. Gauduin, M.-C., G. P. Allaway, P. J. Maddon, C. F. Barbas, D. R. Burton, and R. A. Koup. 1996. Effective ex vivo neutralization of plasma HIV-1 by recombinant immunoglobulin molecules. J. Virol. 70:2586-2592.
15. Gauduin, M.-C., G. P. Allaway, W. C. Olson, R. Weir, P. J. Maddon, and R. A. Koup. 1998. CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates. J. Virol. 72:3475-3478.
16. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
17. Jacobson, J. M., I. Lowy, C. V. Fletcher, T. J. O'Neill, D. N. H. Tran, T. J. Ketas, A. Trkola, M. E. Klotman, P. J. Maddon, W. C. Olson, and R. J. Israel. 2000. Single-dose safety, pharmacology and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182:326-329.
18. Ketas, T. J., I. Frank, P. J. Klasse, B. M. Sullivan, J. P. Gardner, C. Spenlehauer, M. Nesin, W. C. Olson, J. P. Moore, and M. Pope. 2003. Hum, immunodeficiency virus type 1 attachment, coreceptor and fusion inhibitors are active against both direct and trans infection of primary cells. J. Virol. 77:2762-2767.
19. Lalezari, J. P., K. Henry, M. O'Hearn, J. S. G. Montaner, P. J. Piliero, B. Trottier, M. S. Walmsley, C. Cohen, D. R. Kuritzkes, J. J. Eron, J. Chung, R. DeMasi, P. L. Donatacci, C. Drobnes, J. Delehanty, M. Salgo, and the TORO I Study Group. 2003. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348:2175-2185.
20. Lazzarin, A., B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H. J. Stellhrink, J. F. Delfraissy, J. Lange, L. Huson, R. DeMasi, C. Wat, J. Delehanty, C. Drohnes, M. Salgo, and the TORO 2 Study Group. 2003. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:2186.
21. Mouton, Y., S. Alfandari, M. Valette, F. Cartier, P. Dellamonica, G. Humhert, J. M. Lang, P. Massip, D. Mechali, P. Leclercq, J. Modai, and H. Portier. 1997. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 11:F101-F105.
22. Nagashima, K. A., D. A. D. Thompson, S. I. Rosenfield, P. J. Maddon, T. Dragic, and W. C. Olson. 2001. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. 183:1121-1125.
23. O'Hara, B. M., and W. C. Olson. 2002. HIV entry inhibitors in clinical development. Curr. Opin. Pharmacol. 2:523-528.
24. Palella, F. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Asehman, S. D. Holmberg, and The HIV Outpatient Study Investigators. 1998. Declining morbidity and mortality among patients with advanced Human Immunodeficiency Virus Infection. N. Engl. J. Med. 338:853.
25. Palella, F. J., M. Deloria-Knoll, J. S. Chmiel, A. C. Moorman, K. C. Wood, A. E. Greenberg, S. D. Holmberg, and HIV Outpatient Study Investigators. 2003. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Intern. Med. 138:620-626.
26. Philpott, S., B. Weiser, K. Anastos, C. M. Kitchen, E. Robison, W. A. Meyer, H. S. Sacks, U. Mathur-Wagh, C. Brunner, and H. Burger. 2001. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J. Clin. Investig. 107:431-438.
27. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. 100:4144-4149.
28. Scarlatti, G., E. Tresoldi, A. Bjorndal, R. Fredriksson, C. Colognesi, H. K. Deng, M. S. Malnati, A. Plebani, A. G. Siccardi, D. R. Littman, E. M. Fenyo, and P. Lusso. 1997. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Natl. Med. 3:1259-1265.
29. Shearer, W. T., R. J. Israel, S. Starr, C. V. Fletcher, D. Wara, M. Rathore, J. Church, J. DeVille, T. Fenton, B. Graham, P. Samson, S. Staprans, J. McNamara, J. Moye, P. J. Maddon, and W. C. Olson. 2000. Recombinant CD4-IgG2 in HIV-1 infected children: Phase I/II study. J. Infect. Dis. 182:1774-1779.
30. Skrabal, K., V. Trouplin, B. Labrosse, V. Obry, F. Damond, A. J. Hanee, F. Clavel, and F. Mammano. 2003. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 17:809-814.
31. Trkola, A., T. Ketas, V. N. KewalRamani, F. Endorf, J. M. Binley, H. Katinger, J. Robinson, D. R. Littman, and J. P. Moore. 1998. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J. Virol. 72:1876-1885.
32. Trkola, A., T. J. Ketas, K. A. Nagashima, L. Zhao, T. Cilliers, L. Morris, J. P. Moore, P. J. Maddon, and W. C. Olson. 2001. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75:579-588.
33. Trkola, A., A. P. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. Barbas, D. R. Burton, D. D. Ho, and J. P. Moore. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG2. J. Virol. 69:6609-6617.
34. von Briesen, H., M. Grez, H. Ruppach, I. Raudonat, R. E. Unger, K. Becker, B. Panbans, U. Dietrich, and H. Rubsamen-Waigmann. 1999. Selection of HIV-1 genotypes by cultivation in different primary cells. AIDS 13:307-315.
35. Xiao, L., D. L. Rudolph, S. M. Owen, T. J. Spira, and R. B. Lal. 1998. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 12:F137-F143.
36. Yeni, P. G., S. M. Hammer, C. C. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2002. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288:222-235.
37. Zhang, Y. J., T. Dragic, Y. Cao, L. Kostrikis, D. S. Kwon, D. R. Littman, V. N. KewalRamani, and J. P. Moore. 1998. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 72:9337-9344.
38. Zhu, P., W. C. Olson, and K. H. Roux. 2001. Structural flexibility and functional valency of CD4-IgG2 (PRO 542): potential for crosslinking HIV-1 envelope spikes. J. Virol. 75:6682-6686.